Patrick Eimerman

Company: SAGA Diagnostics

Job title: Vice President, Business Development & Partnerships

Seminars:

Next-Gen MRD: Increasing Access to Ultrasensitive ctDNA Assessment for Biomarker Discovery, Development, & CDx Programs 11:50 am

The Pathlight MRD test is an ultrasensitive, cost-effective approach to MRD detection and quantification to <1 PPM using WGS proprietary dPCR methods to track structural variants Structural Variants (SVs) are highly prevalent across indications and are an ideal pan-cancer biomarker for determining MRD status Clinical studies in breast and ovarian cancers demonstrate improved detection of…Read more

day: Day 2 - Track A (1)